• FDA approves Jakafi for acute graft-versus-host disease

    3 monthes ago - By Healio

    The FDA approved ruxolitinib for the treatment of steroid-refractory acute graft-versus-host disease among adults and children aged 12 years and older.
    Ruxolitinib - a first-in-class JAK1/JAK2 inhibitor - is the first FDA-approved treatment for this condition. The drug also is indicated for treatment of polycythemia vera in adults who had an inadequate response to or are intolerant of hydroxyurea, as well as for adults with intermediate- or high-risk myelofibrosis.
    Patients with steroid-refractory acute GVHD - a complication of hematopoietic bone marrow
    Read more ...


  • First Mesothelioma Treatment in 15 Years Approved

    First Mesothelioma Treatment in 15 Years Approved

    3 monthes ago - By Web MD

    The new device was approved under the Humanitarian Device Exemption, which was created to encourage innovation in rare diseases.
    Read more ...